Immunic begins phase II immunotherapy for COVID-19

By The Science Advisory Board staff writers

June 15, 2020 -- Immunic has enrolled the first COVID-19 patients in a phase II clinical trial of IMU-838, a selective oral dihydroorotate dehydrogenase (DHODH) inhibitor.

Approximately 230 patients will be enrolled in 10 to 35 centers in the U.S., Germany, and other European countries. The study will be a prospective, multicenter, randomized, placebo-controlled, double-blind clinical trial in patients with moderate COVID-19, designed to evaluate efficacy, safety, and tolerability of IMU-838. Data is expected to be available later this year.

To date, IMU-838 has already been tested in about 650 individuals in previous studies.

IMU-838 is an orally available, next-generation selective immune modulator that inhibits intracellular metabolism of activated immune cells (T and B cells) by blocking the DHODH enzyme. The molecule has also been shown to possess antiviral effects, independent of specific viral proteins, indicating that it may be broadly applicable against multiple viruses.

IMU-838 is also being tested for treatment of relapsing-remitting multiple sclerosis, ulcerative colitis, and Crohn's disease.

Copyright © 2020
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here